CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML

Purpose: Ponatinib is the only approved tyrosine kinase inhibitor (TKI) suppressing BCR-ABL1T315I-mutated cells in chronic myeloid leukemia (CML). However, due to side effects and resistance, BCR-ABL1T315I-mutated CML remains a clinical challenge. Hydroxyurea (HU) has been used for cytoreduction in...

Full description

Bibliographic Details
Main Authors: Mathias Schneeweiss-Gleixner, Konstantin Byrgazov, Gabriele Stefanzl, Daniela Berger, Gregor Eisenwort, Chantal Blanche Lucini, Susanne Herndlhofer, Sandra Preuner, Klara Obrova, Petra Pusic, Nadine Witzeneder, Georg Greiner, Gregor Hoermann, Wolfgang R. Sperr, Thomas Lion, Michael Deininger, Peter Valent, Karoline V. Gleixner
Format: Article
Language:English
Published: Elsevier 2019-12-01
Series:EBioMedicine
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396419307455

Similar Items

Similar Items